Block Admission Application & Interim Review

 

TIDMMDST 
 
RNS Number : 1200X 
Medicsight Plc 
01 December 2010 
 

 
 
+------------------------------+------------------------------+ 
| Press Release                |            01 December  2010 | 
+------------------------------+------------------------------+ 
 
                                 Medicsight PLC 
                        ("Medicsight" or "the Company") 
 
                  Block Admission Application & Interim Review 
      Block admission return for the period 1 June 2010 to 1 December 2010 
 
On 5 September 2008, a block admission was made to AIM for 11,731,667 ordinary 
shares of 5 pence each in the Company ('Ordinary Shares') which may be issued 
pursuant to the Company's share option schemes A-H. 
 
On 5 March 2009, a block admission was made to AIM for 1,805,000 Ordinary Shares 
which may be issued pursuant to the Company's share option schemes I. 
 
On 9 September 2009, a block admission was made to AIM for 8,148,750 Ordinary 
Shares which may be issued pursuant to the Company's share option schemes J and 
K. 
 
On 2 June 2010, a block admission was made to AIM for 100,000 Ordinary Shares 
which may be issued pursuant to the Company's share option schemes L. 
 
During the period, the following changes to the block admissions occurred: 
 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share option   |     No. of |    No. of |   No. of |   Balance |      Date | 
| schemes        |   Ordinary |  Ordinary | Ordinary |        of |        of | 
|                |      Share |     Share |    Share |  Ordinary | admission | 
|                |    options |   options |  options |    Shares |           | 
|                | originally | forfeited | admitted |   options |           | 
|                | admitted & |    during |    under |    in the |           | 
|                |      share |       the |   scheme |    scheme |           | 
|                |    options |   period' |   during |    at the |           | 
|                | not issued |           |   period |    end of |           | 
|                |     at the |           |          |       the |           | 
|                |   start of |           |          |    period |           | 
|                | the period |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |     62,500 |    62,500 |        - |         - |  05/09/08 | 
| Plan 'A'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |    172,500 |    22,500 |        - |   150,000 |  05/09/08 | 
| Plan 'B'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |     85,000 |         - |        - |    85,000 |  05/09/08 | 
| Plan 'C'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |          - |         - |        - |         - |  05/09/08 | 
| Plan 'D'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |    833,333 |    43,333 |        - |   790,000 |  05/09/08 | 
| Plan 'E'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |     50,000 |         - |        - |    50,000 |  05/09/08 | 
| Plan 'F'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |    150,000 |         - |        - |   150,000 |  05/09/08 | 
| Plan 'G'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |          - |         - |        - |         - |  05/09/08 | 
| Plan 'H'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |    135,000 |    26,667 |        - |   108,333 |  05/03/09 | 
| Plan 'I'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |  7,041,041 |   202,481 |        - | 6,838,560 |  09/09/09 | 
| Plan 'J'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |    300,000 |         - |        - |   300,000 |  09/09/09 | 
| Plan 'K'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
| Share Option   |    100,000 |         - |        - |   100,000 |  02/06/10 | 
| Plan 'L'       |            |           |          |           |           | 
+----------------+------------+-----------+----------+-----------+-----------+ 
 
                                    - Ends - 
 
For further information, please contact: 
+------------------------------------+--------------------------+ 
| Medicsight plc                     |                          | 
+------------------------------------+--------------------------+ 
| Allan Rowley, CEO                  |      Tel: [phone] | 
|                                    |                     7950 | 
+------------------------------------+--------------------------+ 
|                                    |      www.medicsight.com  | 
+------------------------------------+--------------------------+ 
| Daniel Stewart & Co                |                          | 
+------------------------------------+--------------------------+ 
| Emma Earl                          |     Tel: [phone] | 
|                                    |                     6550 | 
+------------------------------------+--------------------------+ 
|                                    | www.danielstewart.co.uk  | 
+------------------------------------+--------------------------+ 
Media enquiries: 
+-------------------------------------+------------------------+ 
| Abchurch                            |                        | 
+-------------------------------------+------------------------+ 
|                                     | www.abchurch-group.com | 
+-------------------------------------+------------------------+ 
| Heather Salmond                     |   Tel: [phone] | 
|                                     |                   7704 | 
+-------------------------------------+------------------------+ 
| [e-mail]  |                        | 
+-------------------------------------+------------------------+ 
| Simone Elviss                       |   Tel: [phone] | 
|                                     |                   7728 | 
+-------------------------------------+------------------------+ 
| [e-mail]    |                        | 
+-------------------------------------+------------------------+ 
| Quincy Allan                        |   Tel: [phone] | 
|                                     |                   7710 | 
+-------------------------------------+------------------------+ 
| [e-mail]     |                        | 
+-------------------------------------+------------------------+ 
 
Notes to editors 
Medicsight plc is a UK-headquartered, research driven, leading developer of 
computer-aided detection (CAD) and image analysis software for the medical 
imaging market. The CAD software automatically highlights suspicious areas on 
computerised tomography (CT) scans of the colon and lung, helping radiologists 
to identify, measure and analyse potential disease and early indicators of 
disease. Medicsight's CAD software has been validated using one of the world's 
largest and most population diverse databases of verified patient CT scan data. 
Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly 
integrated with the advanced 3D visualisation workstations of several 
industry-leading imaging equipment partners. 
 
About Computer-Aided Detection 
With increasingly sophisticated radiological imaging hardware such as 
Multi-Detector CT scanners, radiologists are facing a growing challenge in the 
amount of detailed patient image data that they must review for each patient 
examination. Some CT scan examinations generate as many as 2000 images per 
patient. Review of this data by the radiologist is not only time-consuming but 
also prone to error due to reader fatigue. CAD software can help the reviewing 
radiologist by analysing the image data and automatically highlighting 
suspicious regions of interest for closer inspection. Without CAD software some 
potential abnormalities or areas of disease may be overlooked. This can be 
critical for diagnosis and the management of patient outcomes as early detection 
of disease greatly increases the probability of successful treatment and a 
positive therapeutic outcome. In addition to supporting individual radiologists 
CAD also has the potential to help standardise CT interpretation across both 
individuals and institutions thereby supporting population based screening 
programmes. 
 
About Medicsight's CAD software 
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm 
to analyse CT scans of the colon and lung and automatically highlight suspicious 
areas that may be indicators of disease. CAD may highlight areas easily 
overlooked by the reviewing radiologist, such as small lesions or regions that 
are hidden from view behind folds in the colon or normal structures and 
surrounding tissue in the lung. 
 
Both CAD products seamlessly integrate with the advanced 3D visualisation 
platforms of industry-leading imaging equipment partners. The integrated systems 
provide sophisticated image viewing capabilities, including 3D reconstructed 
image data, with the added advantage of demonstrating automatic CAD findings to 
assist clinical end users in the detection and analysis of disease. This allows 
clinical end users to perform either a 'second read', where CAD findings are 
displayed to the user after completion of an initial review of the CT scan data, 
or a 'concurrent read' where CAD findings are displayed during the user's 
initial review of the original CT scan images. 
 
Since inception, Medicsight has developed close and lasting relationships with 
some of the world's foremost clinicians in product related areas. This provides 
the Company with a wealth of clinical expertise and dedicated clinical research 
to support ongoing product development. Medicsight also collaborates with a 
number of leading academic institutions and clinical research programmes 
worldwide to develop the Company's comprehensive database of population diverse 
verified patient CT scan data, thus allowing Medicsight's products to be 
validated to the highest possible standards. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCWGGRWGUPUGMU